Improving patient outcomes through early cancer detection.
Naveris develops highly sensitive blood tests, liquid biopsies, that identify viral cancers significantly earlier than is possible with scans or traditional biopsies.
Naveris’ lead product, NavDx®, is a liquid biopsy that uses proprietary technology to enable ultrasensitive surveillance of HPV-related cancer.